Communiqués Alterity Therapeutics Limited Nasdaq

Actions

ATHE

US02155X2053

Marché Fermé - Nasdaq Autres places de cotation 21:39:53 31/05/2024			Varia. 5j.	Varia. 1 janv.
1,87 ^USD	-0,54%		-6,50%	-24,90%

08/05	Le comité de surveillance des données de l'étude de phase 2 d'Alterity Therapeutics recommande la poursuite de l'essai clinique comme prévu après un troisième examen	CI
29/04	Alterity Therapeutics Limited présente de nouvelles données démontrant le potentiel de l'ATH434 dans le traitement de maladies neurodégénératives rares	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund	26/03	AQ
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund	26/03	PU
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	15/03	PU
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02	AQ
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week	29/01	AQ
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones	22/01	AQ
Alterity Therapeutics : Presentation to Extraordinary General Meeting	28/12	PU
Alterity Therapeutics : Target Market Determination (TMD) for the placement options offered under the Company’s prospectus dated 29 December 2023	29/12	PU
Alterity Therapeutics : Target Market Determination (TMD) for the free attaching SPP options offered under the Company’s prospectus dated 29 December 2023	29/12	PU
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer	21/12	AQ
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress	04/12	AQ
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease	04/12	AQ
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	30/11	PU
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy	27/11	AQ
Alterity Therapeutics : Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434	15/11	PU
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy	08/11	AQ
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	31/10/23	PU
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report	30/10/23	AQ
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder	31/08/23	AQ
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s	23/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Alterity Therapeutics Limited Nasdaq

Actions

ATHE

US02155X2053

Communiqués

Filtres